Cochrane · systematic review · CD000067
Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease
Chande, N, Patton, PH, Tsoulis, DJ, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
19
current version
GRADE rated
19
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 15 · 78.9%Low 4 · 21.1%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Azathioprine or 6‐mercaptopurine versus placebo for maintenance of remission in Crohn's disease
Population: maintenance of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maintenance of remission (sensitivity analysis excluding Candy 1995) Azathioprine or 6‐mercaptopurine vs placebo | RR 1.19 [1.05, 1.34] | 6 studies · 489 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Azathioprine or 6‐mercaptopurine vs placebo | RR 1.29 [1.02, 1.64] | 6 studies · 359 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Azathioprine or 6‐mercaptopurine vs placebo | RR 3.12 [1.59, 6.09] | 7 studies · 661 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Azathioprine or 6‐mercaptopurine vs placebo | RR 2.45 [1.22, 4.9] | 4 studies · 556 participants | Very low Downgraded: risk of bias, imprecision |
Azathioprine or 6‐mercaptopurine versus mesalazine or sulfasalazine for maintenance of remission in Crohn's disease
Population: maintenance of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maintenance of remission Azathioprine or 6‐mercaptopurine vs mesalazine or sulfasalazine | RR 1.09 [0.88, 1.34] | 2 studies · 166 participants | Low Downgraded: risk of bias, imprecision |
Adverse events Azathioprine or 6‐mercaptopurine vs mesalazine or sulfasalazine | RR 8.77 [0.54, 142.51] | 1 study · 45 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Azathioprine or 6‐mercaptopurine vs mesalazine or sulfasalazine | RR 1.86 [0.87, 3.97] | 2 studies · 290 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Azathioprine or 6‐mercaptopurine vs mesalazine or sulfasalazine | RR 9.37 [1.84, 47.72] | 2 studies · 235 participants | Very low Downgraded: risk of bias, imprecision |
Azathioprine versus budesonide for maintenance of remission in Crohn's disease
Population: maintenance of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maintenance of remission Azathioprine vs budesonide | RR 1.65 [1.13, 2.42] | 1 study · 77 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Azathioprine vs budesonide | RR 5.13 [0.25, 103.43] | 1 study · 77 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Azathioprine vs budesonide | RR 5.13 [0.25, 103.43] | 1 study · 77 participants | Very low Downgraded: risk of bias, imprecision |
Azathioprine and infliximab versus infliximab for maintenance of remission in Crohn's disease
Population: maintenance of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maintenance of remission Azathioprine and infliximab vs infliximab | RR 1.02 [0.74, 1.4] | 1 study · 36 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Azathioprine and infliximab vs infliximab | RR 1.6 [0.33, 7.86] | 1 study · 45 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Azathioprine and infliximab vs infliximab | RR 2.42 [0.1, 56.46] | 1 study · 45 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Azathioprine and infliximab vs infliximab | RR 2.42 [0.1, 56.46] | 1 study · 45 participants | Very low Downgraded: risk of bias, imprecision |
6‐Mercaptopurine versus methotrexate for maintenance of remission in Crohn's disease
Population: maintenance of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Maintenance of remission 6‐Mercaptopurine vs methotrexate | RR 0.94 [0.47, 1.85] | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events 6‐Mercaptopurine vs methotrexate | RR 0.65 [0.31, 1.38] | 1 study · 57 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events 6‐Mercaptopurine vs methotrexate | RR 0.68 [0.17, 2.75] | 1 study · 57 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events 6‐Mercaptopurine vs methotrexate | RR 0.68 [0.17, 2.75] | 1 study · 57 participants | Very low Downgraded: risk of bias, imprecision |